Germ Cell Cancer Clinical Trial
Official title:
Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors
NCT number | NCT02303015 |
Other study ID # | DaTeCa01 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 2014 |
Est. completion date | June 2023 |
Verified date | November 2023 |
Source | Rigshospitalet, Denmark |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to identify genetic variations in survivors of testicular cancer and connect these variations to differences in risks of late effects.
Status | Completed |
Enrollment | 430 |
Est. completion date | June 2023 |
Est. primary completion date | March 2023 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 15 Years and older |
Eligibility | Inclusion Criteria: - Danish citizen - Diagnosed with germ cell cancer from 1984 to 2007 - Treated initially at a Danish hospital - Treated with standard treatment regimens. Exclusion Criteria: - Treated initially at a foreign hospital |
Country | Name | City | State |
---|---|---|---|
Denmark | Dept. of Oncology, Rigshospitalet | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Renal toxicity (Identify genetic variations predicting renal toxicity) | Identify genetic variations predicting renal toxicity. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00996710 -
Genomic Structural Variation in Cancer Susceptibility
|
||
Active, not recruiting |
NCT01453660 -
Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls
|
||
Completed |
NCT01242631 -
Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer
|
Phase 2 | |
Completed |
NCT01851200 -
Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors
|
Phase 2 | |
Not yet recruiting |
NCT06275854 -
YASU Research Registry: For Young Adults With Cancer
|
||
Recruiting |
NCT04897321 -
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
|
Phase 1 | |
Not yet recruiting |
NCT06329323 -
SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours
|